Pfizer Inc. PFE, +1.01% announced an agreement to develop and commercialize Medivation Inc.'s MDVN Dimebon, an investigational treatment for Alzheimer's and Huntington's diseases, in a deal valued at ...

Pfizer Inc., with research operations in Groton, and Medivation Inc. said Monday that their drug candidate Dimebon failed in a second late-stage clinical trial, as it did not improve symptoms of the ...

The drug appears to work no better than a placebo in halting the disease. March 03, 2010— -- Dimebon, a once-promising new Alzheimer's drug from Pfizer Inc., may be no more effective than a ...

Utter the word "Dimebon" to any neuroscientist studying Alzheimer's disease these days, and you'll likely hear a heavy sigh. "You mean 'Dimebomb'?" asks Robert Moir, assistant professor of neurology ...

One of the most promising drugs in Alzheimer's disease research just got a little more mysterious. Dimebon, a Russian antihistamine being developed by San Francisco-based Medivation in partnership ...

NEW YORK, NY and SAN FRANCISCO, CA -- (MARKET WIRE) -- 04/11/11 -- Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from the Phase 3 HORIZON trial of the ...

The last flickering hope that Medivation's Dimebon could help Alzheimer's disease patients has just been extinguished. The biotech announced this morning that a 12-month study of the drug failed to ...

January 18, 2012 — Topline results of a phase 3 trial of dimebon, also called latrepirdine, on top of ongoing treatment with donepezil has shown no benefit in patients with mild to moderate ...

SAN FRANCISCO (MarketWatch) -- Medivation Inc. shares jumped 23% to $19.94 in Monday morning trade after the San Francisco-based company announced that the benefits of Dimebon, Medivation's lead ...

Dimebon appears as one bright light in a field of less-than-stellar clinical trial results of late. But like many stars that suddenly explode into view, is the compound destined to become a black hole ...

This story was updated on 15 February 2010. 12 February 2010. The results of the first U.S. Phase 2 trial for Dimebon in Huntington disease are finally out in print. The February Archives of Neurology ...

Another failed clinical trial has sent dimebon to the trash heap. Jan. 17, 2012— -- Another failure in phase III clinical testing has finally sent the investigational Alzheimer's disease drug ...